Peter Finan

Pete joined Epidarex in 2014. He has more than 20 years of experience in drug discovery within the pharmaceutical industry.

Prior to joining Epidarex, Pete was Global Head of the Respiratory Disease Area and Site Head for the Novartis Institute of BioMedical Research in the UK. In this role, he had strategic and operational oversight for the respiratory portfolio from target discovery through to proof-of-concept trials in the clinic.

Pete is a former Executive Director of the Novartis Developmental and Molecular Pathways Platform based in Cambridge, Massachusetts. In this capacity, he led target discovery, validation and early drug discovery programs across a wide range of therapeutic areas including oncology, neuroscience, regenerative medicine, autoimmunity and inflammation. The approaches used to dissect signaling pathways and identify novel therapeutic targets have been extensively published in Nature and Cell. Pete led the initiation of the PI 3-kinase drug discovery program within Novartis and was awarded the Novartis Leading Scientist Award in 2007.

Earlier in his career, Pete worked at Cancer Research UK and the Yamanouchi Research Institute (now Astellas) and served as the Head of Biology at Karus Therapeutics.

Pete currently serves on the Boards of Directors of Clyde Biosciences Ltd., Enterprise Therapeutics Ltd., Leucid Bio Ltd., Epidarex Exeed, Epsilogen Ltd., Eternygen GmbH (observer), Topas Therapeutics GmbH (observer) and Lunac Therapeutics Ltd. In addition to his role at Epidarex, he is a member of the Board of Directors and Scientific Advisory Board of the Keystone Symposia.

Pete holds a B.Sc. and Ph.D. in Biochemistry and Molecular Biology from the University of Leeds.